Compare Merck & Co., Inc. (MRK) vs ProShares UltraPro QQQ ETF (TQQQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs ProShares UltraPro QQQ ETF — how do they compare? Merck & Co., Inc. trades at $126.26 (market cap $307.25B), while ProShares UltraPro QQQ ETF trades at $70.96. The key difference: Merck & Co., Inc. pays a 2.73% dividend while ProShares UltraPro QQQ ETF pays none, and Merck & Co., Inc. is trading nearer its 52-week high, ProShares UltraPro QQQ ETF nearer its low. Which is the better fit depends on your goals.
| MRK | TQQQ | |
|---|---|---|
Market Cap | $307.25B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $129.52 | $87.22 |
52-Week Low | $77.60 | $37.89 |
Enterprise Value | $350.66B | — |
Dividend Yield | 2.73% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $126.27, down 0.96% on the day, with a neutral technical signal and strong fundamental performance. The company reported robust 2025 results with $65.01B revenue and $18.25B net income, beating EPS estimates in recent quarters. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while analyst consensus remains bullish with a $137.30 price target.
Outlook is positive driven by earnings momentum and strategic M&A, but risks include patent expirations and competitive pressures. The stock offers a dividend yield with upcoming payment, supporting income investors. Valuation multiples are elevated, requiring sustained growth to justify current levels amid macroeconomic uncertainties.
TQQQ trades at $67.65, up 0.18% today, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The ETF's structure amplifies daily Nasdaq-100 returns, yet financial ratios are unavailable as it's a leveraged fund tracking an index. Recent news highlights volatility risks, with articles warning of amplified losses during market downturns despite historical gains in bull markets.
Outlook remains cautious due to leverage decay and bearish technicals; opportunities exist for tactical traders during rebounds, but risks include heightened volatility and structural costs. Long-term holders face potential erosion from daily rebalancing, especially in sideways or declining markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About ProShares UltraPro QQQ ETF
TQQQ is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to three times (3x) the daily performance of the Nasdaq-100 Index. It is one of the most liquid and actively traded instruments in the market, designed for sophisticated traders to amplify short-term bullish exposure to large-cap non-financial growth stocks, predominantly in the technology and communication sectors.
Read more on TQQQ →
